Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imlifidase in Guillain-Barré Syndrome
NCT03943589Phase 2Completed
- Sponsor
- Hansa Biopharma
- Start
- Nov 2019
- Primary completion
- Feb 2024
- Modality
- Therapeutic Enzymes
- Countries
- 3
01
Overview
A Phase 2 trial of imlifidase in Guillain-Barré syndrome (GBS), sponsored by Hansa Biopharma. Started Nov 2019; status: completed.
02
Drugs
imlifidase
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on NCT03943589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03943589.